In-silico prediction of novel targets for mirtazapine in Rett syndrome
Ottavia Maria Roggero, Nicolò Gualandi, Viviana Ciraci, Vittoria Berutto, Emanuele Carosati, Enrico Tongiorgi · FENS Forum 2024
Mirtazapine (MTZ) is a racemic antidepressant drug, consisting of its S(+) and R(-) - enantiomers in a 50:50 mixture. MTZ has been investigated for its potential in the treatment of Rett syndrome, a neurodevelopmental disorder affecting 1/10.000 young females worldwide. However, the mechanisms of action of MTZ are still unclear. To gain new insights into the pharmacological effects of MTZ, the in-silico prediction of novel targets for MTZ represents a valuable approach. S-MTZ and R-MTZ chemical structures were downloaded from PubChem database to perform a screening of S-/R- MTZ versus 25.717 h
ePoster · Neuroscience